Exploring New Opportunities with Chinese Biopharma: Deal-making and Investment

Map Unavailable

Date — Oct 25
3:00 pm - 5:00 pm

The Nippon Club, 145 West 57th St. (bet. 6th & 7th Aves), NYC

3:00 – 5:00 p.m.
5:00 – 6:30 p.m.

SPEAKERS: (Click names for bios)
Mr. William Burkoth, Executive Director, Pfizer Ventures

Mr. Burkoth is currently an Executive Director of Pfizer Ventures, the venture capital arm of Pfizer Inc. Since joining Pfizer in early 2004, he has played an instrumental role in numerous new venture capital investments, including Avid Radiopharmaceuticals (acquired by Eli Lilly), Clovis Oncology (Nasdaq: CLVS), DVS Sciences (acquired by Fluidigm), Evolution Benefits (acquired by Genstar Capital), and HandyLab (acquired by Becton Dickinson). He currently serves on the board of directors of Biodesy, G-Con Manufacturing, NeuMoDx Molecular, Novocure, Palleon Pharma and RefleXion Medical. He is also a member of the investment committee of the Investment Fund for Health in Africa (IFHA) and BBI Financial Gestão de Recursos (Rio, Brazil).

Prior to joining Pfizer, Mr. Burkoth worked in Business Development at Galileo Pharmaceuticals and at IntraBiotics Pharmaceuticals. Prior to his roles in business development, he was an analyst at Bay City Capital. Mr. Burkoth received a BA in chemistry from Whitman College and an MBA from Columbia Business School.

Dr. Lars E. Birgerson, President & CEO, Adlai Nortye USA

Dr. Birgerson currently serves as Chief Development Officer for Adlai Nortye Ltd. and President & CEO for Adlai Nortye USA Inc. Since leaving a career in academia, Dr. Birgerson has amassed more than 25 years of biopharmaceutical industry experience in senior positions, and is personally responsible for several successful NDA filings. He has held leading positions with companies such as Bristol-Myers Squibb, Genentech, Roche, and Pharmacia (now Pfizer) where his work has focused primarily on Medical Affairs and Late Stage Development. He has deep experience on issues related to clinical development, product/indication launch, KOL engagement, real-world evidence, and organizational effectiveness and experience in most therapeutic areas (primary care, women’s health, immunology, virology, etc.), with a strong focus on oncology and immuno-oncology. Dr. Birgerson has served on numerous governance committees, including Commercial leadership teams, R&D executive teams, and global portfolio governance committees.

Dr. Birgerson received his MD, PhD and completed residencies in Obstetrics and Gynecology, General Surgery, Gynecological Oncology, and Urological Surgery at Uppsala University in Sweden.

Dr. James T. Lee, Associate Principal, Defined Health

Dr. Lee has extensive experience leading oncology projects, particularly in immuno-oncology, where he has led client engagements ranging from commercial opportunity assessments to portfolio/platform management. He has helped clients navigate potential BD&L issues, ranging from in- and out-licensing opportunities to evaluating pre-commercial biotech clinical development paths.

Before joining Defined Health, Dr. Lee was a Scientist and Oncology Personalized Medicine Project Leader and was involved in numerous preclinical neuroscience and translational oncology projects at Psychogenics. During that time, he managed a diverse collaborative effort to discover and validate drug discovery and preclinical tools for both clients and patients. Prior to that he completed his postdoctoral fellowship at Columbia University in Oncology in the laboratory of Dr. Wei Gu working with tumor suppressors p53 and PTEN (in collaboration with Dr. Ramon Parsons).

Dr. Lee received a BA from Rutgers University and a PhD in Neuroscience from Emory University, where he studied the molecular mechanisms of Parkinson’s disease. He is a member of the ASCO, AACR, ASH, NYAS, and SITC.

Dr. Andy Li, Founding Partner, BioSense

Dr. Li has more than 25 years of biomedical research and biopharmaceutical industry experience with proven track records in global drug development in multiple therapeutic areas, alliance management, and business development. He previously held management positions at GSK, Abbott and most recently, Daiichi Sankyo. During his extensive career, he worked directly on highly successful projects and products, including HUMIRA and Olmesartan. He also managed and led the development, registration, and commercialization efforts in key markets, including the U.S., Europe, Japan, China, Korea, Taiwan, Brazil and others.

Dr. Li has a PhD from Albert Einstein College of Medicine and an MBA from Duke University.

Dr. Anjiang (Vincent) Liu, Deputy General Manager of Strategic Product Development Center, Fosun Pharma

Dr. Liu has worked in the International Business Division of Wanbang Biopharmaceutical, a subsidiary of Shanghai Fosun Pharmaceutical Group, since 2009. Past career achievements include helping the company to raise $500 million in private equity funding from overseas, setting up two joint ventures with large US and Canadian companies in China, investment in a healthcare service company in the US, and three pharmaceutical licensing/business development transactions which could potentially bring over $1 billion in future product revenue opportunities to the Chinese market. Dr. Liu also serves as Senior Advisor to Wanbang Biopharmaceutical.

Dr. Liu received his MBA from the University of Rochester and his PhD in Molecular Pathology from Drexel University.

Dr. Sam Murphy, VP and Head of International Business Development, Shenzhen Salubris Pharmaceuticals Co Ltd. and Salubris Biotherapeutics Inc.

Dr. Murphy currently serves as VP and Head of International Business Development for Salubris Pharmaceuticals and its US subsidiary SalubrisBio. His role encompasses origination, evaluation, and execution of licensing transactions, strategic investments and acquisitions outside of China. He leads the externally-facing efforts ongoing at Salubris to pivot towards an innovation-driven product portfolio and a global presence. Prior to joining Salubris, Dr. Murphy worked for ten years in strategy consulting and transaction advisory services across several global firms including IMS (now IQVIA) and Simon-Kucher & Partners. His commercial strategy engagements encompassed 18 of the top 25 pharmaceutical companies, as well as numerous small and mid-sized biotech companies, with an emphasis on pricing and market access. Past transaction advisory work included licensing and acquisitions collectively exceeding $2B USD, and he also supported early-stage financing for a number of emerging pharma/biotech companies.

Dr. Murphy completed his B.A. in Biochemistry, Ph.D. in Molecular Biology and Post-Doctoral Fellowship in Gene Therapy and Translational Medicine at the University of Pennsylvania, where he focused principally on gene therapy during his 13 years of bench research. He was also awarded a Presidential Management Fellowship in which he supported policy development around a $1B congressional initiative to build the national biodefense stockpile. Dr. Murphy is currently a board member at GO Therapeutics and MedAlliance S.A., as well as a board observer at Mercator Medsystems.

Mr. Joshua L. Berlin, Executive Director & Editor, New Ventures, BioCentury Inc.

Mr. Berlin is responsible for developing editorial and business opportunities for BioCentury Inc. with a particular focus on China and Asia. BioCentury is a leading global provider of analysis and data for biopharma executives and investors. Prior to joining BioCentury in 2014, he created and led the emerging markets group for Elsevier Business Intelligence (now Informa plc) for seven years, including PharmAsia News and the annual PharmAsia Summit. Mr. Berlin is on the organizing committee of the BioCentury-BayHelix China Healthcare Summit, an annual VIP event organized by BioCentury and BayHelix in collaboration with McKinsey & Co. He is a co-founder of the China Healthcare Dinner with C-Level Executives, held annually in San Francisco during the week of the JP Morgan Healthcare Conference, and also serves on the editorial board for the World Korea Medical Journal.

Regular Member Companies may send up to four attendees free of charge, attendance beyond that is $90 per attendee.
Associate Member Companies must pay $130 per attendee.
Non-member Companies interested in attending the event should contact us via email

To register, please email attendees’ names (incl. Mr./Ms./Dr.) and affiliations  to nypharmaforum@didit.com

We will email you a confirmation and payment information if needed.

**A few complimentary seats are available for those who are interested in joining the organization